Soleno Therapeutics Inc. filed a report on September 10, 2025, regarding a serious adverse event linked to the use of VYKAT™ XR, which involved a deceased 17-year-old patient, though the treating physician and company state it was not related to the treatment. The patient had significant health issues including obesity and other comorbidities, emphasizing the need for cautious treatment administration.